Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PREVACID.
ACIPHEX SPRINKLE vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
20 mg orally once daily as delayed-release capsules; maximum dose 40 mg per day.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in healthy subjects; prolonged in CYP2C19 poor metabolizers (up to 3-4 hours). Clinically, the short half-life results in rapid clearance but sustained acid suppression due to irreversible binding to the proton pump.
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Primarily hepatic metabolism (CYP2C19 and CYP3A4); <1% excreted unchanged in urine; approximately 90% of the dose excreted as metabolites in urine and feces via biliary elimination.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor